# Automated cell culture systems

Robotic and software platforms that automate the closed, GMP-grade cell culture and manufacturing steps behind cell and gene therapies — end-to-end automated manufacturing platforms, robotic drug-product handling, and the scheduling/orchestration software coordinating multi-instrument automated workflows — sold by four specialists (Cellares, Multiply Labs, Ori Biotech, HighRes Biosolutions) targeting the labor-intensive, variability-prone manual cell-therapy manufacturing process.

Source: https://en.bioecon.ru/technology/automated-cell-culture-systems/
Updated: 2026-08-19



## Overview and value chain

Markers: [EC: EU GMP Annex 1 (ATMP manufacturing) | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU)]

Automated cell culture systems replace the manual, technician-dependent steps of cell and gene therapy manufacturing — cell isolation, activation, transduction, expansion and formulation — with closed, robotically-operated platforms designed to cut cost, reduce operator-introduced variability and scale production beyond what a manual cleanroom process can support. The category spans full end-to-end manufacturing platforms that automate an entire cell-therapy production run inside a single closed system, robotics-driven modular manufacturing that automates specific high-touch steps (such as drug-product fill and finish) using standard collaborative robots, and the scheduling and orchestration software that coordinates multiple automated instruments into a single validated workflow. Demand is driven directly by the economics of cell-therapy manufacturing: a fully manual process is both expensive (cited cost reductions from automation reach 74% in one documented case) and difficult to scale to the patient volumes autologous and allogeneic cell therapies increasingly require, making automated systems a commercial necessity rather than an optional efficiency upgrade for cell-therapy developers and CDMOs.

The key directions of automated cell culture systems are:
1. **End-to-end automated manufacturing platforms:** closed systems that automate an entire cell-therapy production run — isolation through formulation — inside a single platform, positioned as an alternative to a traditional CDMO's manual cleanroom process.
2. **Robotics-driven modular manufacturing:** collaborative-robot-based automation of specific high-touch manufacturing steps (drug-product handling, fill-finish) integrated into a broader manual or semi-automated process rather than replacing the entire workflow.
3. **Workflow scheduling and orchestration software:** software that coordinates multiple automated lab instruments (liquid handlers, incubators, analyzers) into a single scheduled, auditable workflow, the control layer above the physical automation hardware.
4. **AI-assisted process control:** software layers increasingly integrating AI agents and toolkits into the scheduling and execution layer, positioned as the "open execution layer" connecting automated lab hardware to AI-driven process decisions.

### Sectoral value chain

```
[Cell Source Material] ──> [Automated Isolation/Activation] ──> [Automated Expansion/Culture] ──> [Automated Formulation]
                                                    │
                                          (Workflow Scheduling/Orchestration)
                                                    │
                                                    ▼
[Patient-Ready Cell Product] <─── [QC and Release Testing] <─────┘
```

### Value chain levels

| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Cell source material** | Patient (autologous) or donor (allogeneic) starting cell material entering the manufacturing process. | **In:** Apheresis material or donor cell source.<br>**Out:** Source cells ready for isolation/activation. |
| **Automated isolation/activation** | Robotically isolating and activating the target cell population within a closed system. | **In:** Source cells.<br>**Out:** Isolated, activated cell population. |
| **Automated expansion/culture** | Automated bioreactor or culture-vessel expansion of the activated cell population to manufacturing scale. | **In:** Activated cells.<br>**Out:** Expanded cell population at target cell count. |
| **Automated formulation** | Robotically formulating the expanded cell population into the final drug-product format for fill-finish. | **In:** Expanded cell population.<br>**Out:** Formulated drug product ready for fill-finish. |
| **QC and release testing** | Testing the formulated product against release specifications, increasingly scheduled and tracked through the same orchestration software as the manufacturing steps. | **In:** Formulated drug product.<br>**Out:** QC-released or rejected batch. |
| **Patient-ready cell product** | The released, patient-ready autologous or allogeneic cell therapy product. | **In:** QC-released batch.<br>**Out:** Patient-ready cell therapy product. |

Cross-cutting technologies of the sector:
- **Closed cell-therapy automation:** end-to-end automated platforms that keep the entire manufacturing process within a closed, robotically-operated system from isolation through formulation.
- **Robotic biomanufacturing cell line:** collaborative-robot automation of specific high-touch manufacturing steps within a broader cell-therapy production line.
- **Lab workflow orchestration software:** scheduling and coordination software that sequences multiple automated instruments into a single validated, auditable workflow.

---

## US

The United States hosts two specialists at opposite ends of the automation spectrum: a full end-to-end closed-platform manufacturer and a modular robotics integrator, plus the orchestration-software layer coordinating automated instrument workflows more broadly.

### End-to-end automated manufacturing, modular robotics, workflow orchestration software
- **Cellares:** operates the Cell Shuttle automated cell-therapy manufacturing platform within its "smart factory" (IDMO) model, with a documented case of first-patient dosing on product manufactured entirely on the platform for a partner's cell therapy, positioned as an alternative to conventional CDMO manual manufacturing.
- **Multiply Labs:** deploys collaborative-robot-driven automation for cell-therapy bio-manufacturing, with a documented 74% cost-reduction case study using Universal Robots cobots, targeting the specific high-touch manual steps within a broader manufacturing line rather than the entire process.
- **HighRes Biosolutions:** produces the Cellario workflow-scheduling and orchestration software coordinating multiple automated lab instruments into a single scheduled workflow, recently extending the platform toward AI-agent integration (including an NVIDIA BioNeMo toolkit connection) as an "open execution layer" for automated lab operations.

---

## CN

China's presence in automated cell culture systems is limited to general lab-automation and cell-therapy manufacturing market coverage rather than a confirmed dedicated automation-platform producer: no domestic company's own-domain page confirming a specific automated cell-culture manufacturing platform was found in this screen.

### Market coverage only, no confirmed dedicated automation-platform producer
- **General market visibility only:** searches return industry reporting on China's cell-therapy manufacturing capacity growth rather than a specific domestic company's own commercial automated cell-culture platform.
- **No producer tabled:** without an own-domain page confirming a specific Chinese company's automated cell-culture manufacturing platform, none is listed here — an evidence gap to revisit as the category develops, not a claim that Chinese cell-therapy manufacturers are absent generally.

---

## EU

Europe is represented by the UK specialist whose IRO platform recently earned a distinct FDA manufacturing-technology designation, evidence its automated approach is gaining regulatory as well as commercial traction.

### Automated cell and gene therapy manufacturing, regulatory-designated platforms
- **Ori Biotech (UK):** operates the IRO automated cell and gene therapy manufacturing platform, which received FDA Advanced Manufacturing Technology (AMT) designation and has a documented strategic-partnership dosing milestone with a cell-therapy developer, positioning it alongside Cellares as a full-platform automated-manufacturing alternative to conventional CDMO processes.

---

## Leading companies and research institutes

| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **Cellares** | 🇺🇸 USA | *Cell Shuttle, smart factories (IDMO)* | End-to-end closed automated cell-therapy manufacturing | commercial |
| **Ori Biotech** | 🇬🇧 UK | *IRO platform* | FDA Advanced Manufacturing Technology designation | commercial |
| **Multiply Labs** | 🇺🇸 USA | *Cobot-driven cell-therapy manufacturing automation* | 74% documented cost reduction using Universal Robots cobots | commercial |
| **HighRes Biosolutions** | 🇺🇸 USA | *Cellario OS workflow orchestration software* | Multi-instrument scheduling, AI-agent integration (NVIDIA BioNeMo) | commercial |

---

## Tech stack and innovations

The stack spans full-platform hardware automation, modular robotics automation of specific steps, and the software orchestration layer that increasingly ties automated instruments into an AI-assisted control system.

1. **End-to-End Closed Manufacturing Platforms:**
   - Cellares's Cell Shuttle and Ori Biotech's IRO platform both automate an entire cell-therapy manufacturing run inside a single closed system, the most capital-intensive but most comprehensive automation tier in the category.
   - Both platforms have moved past pilot status to documented commercial traction — first-patient dosing on Cellares's platform, and FDA AMT designation plus a partner dosing milestone for Ori Biotech — evidence the end-to-end approach has cleared real regulatory and manufacturing validation bars, not just demonstrated feasibility.
2. **Modular Robotics Automation:**
   - Multiply Labs applies collaborative robots to specific high-touch manufacturing steps rather than automating the entire process, a lower-capital-intensity entry point that still delivers a documented, substantial cost reduction.
   - This tier targets facilities retrofitting automation into an existing manual process rather than facilities building a fully automated line from scratch.
3. **Workflow Orchestration and AI Integration:**
   - HighRes Biosolutions's Cellario software sits above the physical automation hardware, scheduling and coordinating multiple instruments (liquid handlers, incubators, analyzers) into a single auditable workflow rather than automating a manufacturing step itself.
   - The platform's recent extension toward AI-agent integration, including a named NVIDIA toolkit connection, signals the orchestration layer is becoming the point where AI-driven process decisions get connected to physical lab automation, a distinct and newer commercial direction from the scheduling function alone.

---

## Value chains and production pipelines

### Industrial pipeline of an automated cell-therapy manufacturing run (FDA, EMA oversight)

```
┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Cell Source Material   │ ───> │ 2. Automated Isolation/Act.│
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Automated Formulation  │ <─── │ 3. Automated Expansion     │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. QC and Release Testing │ ───> │ 6. Patient-Ready Product   │
└───────────────────────────┘      └───────────────────────────┘
```

#### Stage 1: Cell source material
Patient (autologous) or donor (allogeneic) starting cell material enters the manufacturing process, the common starting point regardless of which automated platform processes it.

#### Stage 2: Automated isolation/activation
The target cell population is robotically isolated and activated within a closed system, eliminating the manual open-processing steps that introduce operator-dependent variability in conventional manufacturing.

#### Stage 3: Automated expansion/culture
The activated cell population is expanded to manufacturing scale within an automated bioreactor or culture-vessel system, scheduled and tracked by the platform's orchestration layer.

#### Stage 4: Automated formulation
The expanded cell population is robotically formulated into its final drug-product format, the step immediately preceding fill-finish.

#### Stage 5: QC and release testing
The formulated product is tested against release specifications, increasingly scheduled and logged through the same orchestration software coordinating the upstream manufacturing steps.

#### Stage 6: Patient-ready cell product
The QC-released product moves forward as a patient-ready autologous or allogeneic cell therapy, the end point the entire automated manufacturing run was built to reach reliably and at scale.